HK1220720A1 - 疫苗及其使用方法 - Google Patents

疫苗及其使用方法

Info

Publication number
HK1220720A1
HK1220720A1 HK16108634.7A HK16108634A HK1220720A1 HK 1220720 A1 HK1220720 A1 HK 1220720A1 HK 16108634 A HK16108634 A HK 16108634A HK 1220720 A1 HK1220720 A1 HK 1220720A1
Authority
HK
Hong Kong
Prior art keywords
idna
methods
same
vaccines
idna vaccines
Prior art date
Application number
HK16108634.7A
Other languages
English (en)
Inventor
Peter Pushko
Igor Lukashevich
Original Assignee
Medigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigen Inc filed Critical Medigen Inc
Publication of HK1220720A1 publication Critical patent/HK1220720A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/193—Equine encephalomyelitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16108634.7A 2008-07-17 2016-07-20 疫苗及其使用方法 HK1220720A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8148208P 2008-07-17 2008-07-17

Publications (1)

Publication Number Publication Date
HK1220720A1 true HK1220720A1 (zh) 2017-05-12

Family

ID=41550920

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108634.7A HK1220720A1 (zh) 2008-07-17 2016-07-20 疫苗及其使用方法

Country Status (7)

Country Link
US (3) US8691563B2 (zh)
EP (3) EP2310510B1 (zh)
BR (1) BRPI0916186B8 (zh)
DK (2) DK2310510T3 (zh)
ES (2) ES2544702T3 (zh)
HK (1) HK1220720A1 (zh)
WO (1) WO2010008576A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2310510B1 (en) 2008-07-17 2015-05-06 Medigen, Inc. Idna vaccines and methods for using the same
US10602508B2 (en) * 2015-08-10 2020-03-24 Qualcomm Incorporated LTE-direct communication for vehicle-to-vehicle
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
IL315325A (en) 2018-01-04 2024-10-01 Iconic Therapeutics Inc Anti-tissue-mediated antibodies, antibody-drug conjugates, and related methods
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
BR9909173A (pt) * 1998-03-27 2000-12-05 Secr Defence ácido nucleico, mutante de deleção de um alfa-vìrus, adenovìrus recombinante, vìrus vacìnia recombinante, plasmìdeo, vacina, e, processo para produzir uma imune resposta protetora a um alfa-vìrus
FR2779736B1 (fr) * 1998-06-12 2002-12-13 Goemar Lab Sa Genes codant pour des beta-agarases et leur utilisation pour la production d'enzymes de biodegradation des agars
US6296854B1 (en) * 1998-12-07 2001-10-02 The United States Of America As Represented By The Secretary Of The Army Live attenuated Venezuelan Equire encephalitis vaccine
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
ES2345876T3 (es) * 2001-05-31 2010-10-05 Novartis Vaccines And Diagnostics, Inc. Particulas de replicones de alfavirus quimericos.
AU2003902842A0 (en) * 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
WO2005026316A2 (en) * 2003-09-15 2005-03-24 Bioption Ab Alphavirus vaccines
US7459163B2 (en) * 2004-02-25 2008-12-02 University Of Kansas Infectious DNA as a vaccine against west nile and other flaviviruses
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
EP2310510B1 (en) * 2008-07-17 2015-05-06 Medigen, Inc. Idna vaccines and methods for using the same
PT2519266T (pt) * 2009-12-31 2017-11-10 Medigen Inc Vacinas de dna infeccioso contra o vírus chikungunya

Also Published As

Publication number Publication date
EP2977457A3 (en) 2016-05-04
EP3992296A1 (en) 2022-05-04
EP2310510A2 (en) 2011-04-20
ES2544702T3 (es) 2015-09-02
US10653769B2 (en) 2020-05-19
US9968672B2 (en) 2018-05-15
BRPI0916186A2 (pt) 2018-05-29
ES2902787T3 (es) 2022-03-29
EP2977457B1 (en) 2021-09-01
US20180243404A1 (en) 2018-08-30
EP2977457A2 (en) 2016-01-27
US20140178430A1 (en) 2014-06-26
WO2010008576A2 (en) 2010-01-21
BRPI0916186B1 (pt) 2021-03-09
DK2310510T3 (en) 2015-08-03
US20110243989A1 (en) 2011-10-06
EP2310510A4 (en) 2012-01-25
BRPI0916186B8 (pt) 2021-05-25
WO2010008576A3 (en) 2010-04-29
US8691563B2 (en) 2014-04-08
DK2977457T3 (da) 2021-12-06
EP2310510B1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
HK1218427A1 (zh) 改進的疫苗及其使用方法
IL244197A0 (en) Antibodies against cd100 and methods of using them
HK1209626A1 (zh) 納米通道裝置和相關方法
EP2352202A4 (en) FUNCTIONAL DEVICE AND METHOD FOR MANUFACTURING THE SAME
IL287311A (en) Antibodies and processes for their preparation
AU2013201592A1 (en) Improved vaccines and methods for using the same
EP2308884A4 (en) PROCESS FOR THE PREPARATION OF HETEROSUBSTITUTED ALKYLHALOHYDROSILANE AND ITS USE
EP2237857A4 (en) REACTIVE COMPONENT REDUCTION SYSTEM AND METHODS OF USE
EP2307634A4 (en) CLAMP AND USE METHOD FOR THE CLAMP
EP2113169A4 (en) CLEANING DEVICE AND CLEANING METHOD FOR THE DEVICE
HK1220720A1 (zh) 疫苗及其使用方法
HK1163083A1 (zh) 中間體和應用所述中間體製備恩替卡韋的方法
EP2145715A4 (en) WELDING DEVICE AND SETTING DEVICE FOR THE DEVICE
EP2307052A4 (en) ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE
ZA201001029B (en) Vaccines
HK1212698A1 (zh) 噻唑基和噁唑基異喹哪啶以及它們的使用方法
IL201248A (en) Polates are marked f 18 and methods for preparing them
EP2234731A4 (en) ROTARY SPRAYER AND METHODS OF USING THE SAME
GB2465887B (en) Projection device and projection method
EP2388320A4 (en) ANTI-HS6ST2 ANTIBODIES AND USE THEREOF
GB0823333D0 (en) Apparatus and methods
EP2248050A4 (en) LOCATION DESCRIPTION FOR FEDERATION AND DISCOVERY ABILITY
IL213318A0 (en) C1orf59 peptides and vaccines including the same
IL214453A0 (en) Vangli peptides and vaccines including the same
GB0801326D0 (en) Vaccines